Fosun Pharmaceuticals announced that on September 22, 2026, the company repurchased 1.2 million H shares through the Hong Kong Stock Exchange, accounting for 0.23% of the shares issued before the repurchase. The repurchase price range for each share was HK$18.01 to HK$18.23, with a total transaction amount of HK$21.7916 million. The purchased shares are to be held as treasury shares. The repurchase is based on the repurchase authorization passed by the shareholders' meeting on June 16, 2026. The total number of shares authorized to be repurchased is 54.0972 million shares. As of the completion of the repurchase, a total of 11.2305 million shares have been repurchased, accounting for 2.08% of the shares issued on the authorization date. The 30-day period after this repurchase will be suspended for the issuance of new shares and the sale/transfer of treasury shares, until October 22, 2026.

Fosun Pharmaceuticals announced that on September 22, 2026, the company repurchased 1.2 million H shares through the Hong Kong Stock Exchange, accounting for 0.23% of the shares issued before the repurchase. The repurchase price range for each share was HK$18.01 to HK$18.23, with a total transaction amount of HK$21.7916 million. The purchased shares are to be held as treasury shares. The repurchase is based on the repurchase authorization passed by the shareholders' meeting on June 16, 2026. The total number of shares authorized to be repurchased is 54.0972 million shares. As of the completion of the repurchase, a total of 11.2305 million shares have been repurchased, accounting for 2.08% of the shares issued on the authorization date. The 30-day period after this repurchase will be suspended for the issuance of new shares and the sale/transfer of treasury shares, until October 22, 2026.